Zentalis Pharmaceuticals (ZNTL) Competitors $1.29 +0.03 (+2.38%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.30 +0.01 (+0.78%) As of 04/17/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. ABVX, ORIC, STOK, TRML, ETON, ALLO, TRDA, AMLX, ALT, and HRTXShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include ABIVAX Société Anonyme (ABVX), ORIC Pharmaceuticals (ORIC), Stoke Therapeutics (STOK), Tourmaline Bio (TRML), Eton Pharmaceuticals (ETON), Allogene Therapeutics (ALLO), Entrada Therapeutics (TRDA), Amylyx Pharmaceuticals (AMLX), Altimmune (ALT), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. ABIVAX Société Anonyme ORIC Pharmaceuticals Stoke Therapeutics Tourmaline Bio Eton Pharmaceuticals Allogene Therapeutics Entrada Therapeutics Amylyx Pharmaceuticals Altimmune Heron Therapeutics Zentalis Pharmaceuticals (NASDAQ:ZNTL) and ABIVAX Société Anonyme (NASDAQ:ABVX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation. Do insiders and institutionals have more ownership in ZNTL or ABVX? 47.9% of ABIVAX Société Anonyme shares are owned by institutional investors. 3.6% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer ZNTL or ABVX? Zentalis Pharmaceuticals received 53 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. However, 75.00% of users gave ABIVAX Société Anonyme an outperform vote while only 62.00% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformZentalis PharmaceuticalsOutperform Votes6262.00% Underperform Votes3838.00% ABIVAX Société AnonymeOutperform Votes975.00% Underperform Votes325.00% Do analysts rate ZNTL or ABVX? Zentalis Pharmaceuticals currently has a consensus price target of $8.24, indicating a potential upside of 539.10%. ABIVAX Société Anonyme has a consensus price target of $38.00, indicating a potential upside of 493.75%. Given Zentalis Pharmaceuticals' higher probable upside, research analysts plainly believe Zentalis Pharmaceuticals is more favorable than ABIVAX Société Anonyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44ABIVAX Société Anonyme 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility & risk, ZNTL or ABVX? Zentalis Pharmaceuticals has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, ABIVAX Société Anonyme has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Which has stronger valuation and earnings, ZNTL or ABVX? ABIVAX Société Anonyme has lower revenue, but higher earnings than Zentalis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis Pharmaceuticals$67.43M1.37-$292.19M-$2.32-0.56ABIVAX Société AnonymeN/AN/A-$159.90MN/AN/A Is ZNTL or ABVX more profitable? ABIVAX Société Anonyme's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -43.91% -34.96% ABIVAX Société Anonyme N/A N/A N/A Does the media favor ZNTL or ABVX? In the previous week, ABIVAX Société Anonyme had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 2 mentions for ABIVAX Société Anonyme and 0 mentions for Zentalis Pharmaceuticals. ABIVAX Société Anonyme's average media sentiment score of 0.19 beat Zentalis Pharmaceuticals' score of 0.00 indicating that ABIVAX Société Anonyme is being referred to more favorably in the news media. Company Overall Sentiment Zentalis Pharmaceuticals Neutral ABIVAX Société Anonyme Neutral SummaryABIVAX Société Anonyme beats Zentalis Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.64M$6.44B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.31%P/E Ratio-0.526.8821.7717.77Price / Sales1.37231.02379.4097.65Price / CashN/A65.6738.2634.64Price / Book0.215.916.443.98Net Income-$292.19M$142.72M$3.21B$247.44M7 Day Performance4.88%4.33%2.82%1.82%1 Month Performance-27.12%-12.80%-8.67%-6.98%1 Year Performance-89.71%-9.71%11.38%1.49% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals2.0329 of 5 stars$1.29+2.4%$8.24+539.1%-89.9%$92.64M$67.43M-0.52160ABVXABIVAX Société Anonyme2.1256 of 5 stars$5.23-1.7%$38.00+626.6%-57.0%$331.49MN/A0.0061Short Interest ↑Gap DownORICORIC Pharmaceuticals3.4521 of 5 stars$4.59-5.9%$18.86+310.8%-51.1%$326.01MN/A-2.5280Positive NewsSTOKStoke Therapeutics3.3774 of 5 stars$6.01+1.2%$24.67+310.4%-34.4%$325.01M$36.56M-2.86100Analyst RevisionGap DownTRMLTourmaline Bio2.6186 of 5 stars$12.62-1.6%$45.20+258.2%-4.0%$324.15MN/A-4.4844ETONEton Pharmaceuticals2.1056 of 5 stars$11.85+0.2%$27.67+133.5%+356.7%$317.79M$39.01M-53.8620Short Interest ↑Gap DownHigh Trading VolumeALLOAllogene Therapeutics3.0079 of 5 stars$1.43-0.7%$9.29+549.6%-58.7%$310.69M$22,000.00-0.92310News CoverageTRDAEntrada Therapeutics3.1144 of 5 stars$8.19+3.1%$25.67+213.4%-33.5%$307.90M$210.78M5.15110Positive NewsAMLXAmylyx Pharmaceuticals3.0908 of 5 stars$3.46+0.9%$8.00+131.2%+99.0%$306.56M$87.37M-0.91200Analyst RevisionALTAltimmune2.7493 of 5 stars$3.98-6.1%$20.83+423.5%-35.3%$306.52M$20,000.00-2.5750Positive NewsHRTXHeron Therapeutics3.4869 of 5 stars$1.96-6.7%$5.67+189.1%-33.6%$298.57M$144.29M-10.89300 Related Companies and Tools Related Companies ABVX Competitors ORIC Competitors STOK Competitors TRML Competitors ETON Competitors ALLO Competitors TRDA Competitors AMLX Competitors ALT Competitors HRTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZNTL Stock Free ZNTL Stock Alerts